IP Library Granted Patent US 8,735,566
Granted Patent B2
US 8,735,566 · App. 12/053,197 · Granted May 27, 2014

Bacterially derived intact minicells that encompass plasmid free functional nucleic acid for in vivo delivery to mammalian cells

Inventors: Himanshu Brahmbhatt (Bossley Park, AU); Jennifer MacDiarmid (Glebe, AU); Toby Hulf (Castle Cary, GB)
Assignee: Engeneic Molecular Delivery Pty Ltd
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,735,566
App. No.
12/053,197
Granted
May 27, 2014
Kind
B2
Abstract

Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation.

Claims (13)

1. A method for formulating a minicell composition comprising (a) a plurality of intact, bacterially derived minicells, each minicell of said plurality encompassing plasmid-free regulatory RNA, and (b) a pharmaceutically acceptable carrier therefor, the method consisting essentially of co-incubating a plurality of intact, bacterially derived minicells with regulatory RNA in a saline buffer, wherein said regulatory RNA is selected from the group consisting of siRNA, miRNA and shRNA.

2. The method of claim 1 , wherein said co-incubation comprises gentle shaking.

3. The method of claim 1 , wherein said co-incubation lasts about 0.5 hour.

4. The method of claim 1 , wherein said co-incubation lasts about one hour.

5. The method of claim 1 , wherein said buffered saline is in gelatin form.

6. The method of claim 1 , wherein said buffer comprises a 1× phosphate buffer solution.

7. The method of claim 1 , wherein said co-incubation is conducted at a temperature of about 4° C. to about 37° C.

8. The method of claim 1 , wherein said co-incubation is conducted at a temperature of about 20° C. to about 30° C.

9. The method of claim 1 , wherein said co-incubation is conducted at a temperature of about 25° C.

10. The method of claim 1 , wherein said co-incubation is conducted at a temperature of about 37° C.

11. The method of claim 10 , wherein said co-incubation comprises about 10 10 minicells.

12. The method of claim 1 , wherein said co-incubation comprises about 10 7 , 10 8 , 10 9 , 10 10 , 10 11 , 10 12 or 10 13 minicells.

13. The method of claim 1 , wherein said co-incubation comprises about 10 10 minicells.

Assignments (2)
CHANGE OF NAME Recorded Feb 11, 2014
From: ENGENEIC GENE THERAPY PTY LIMITED
To: ENGENEIC MOLECULAR DELIVERY PTY LTD
Reel/Frame 032250/0584 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 14, 2008
From: BRAHMBHATT, HIMANSHU; MACDIARMID, JENNIFER; HULF, TOBY
To: ENGENEIC THERAPY PTY. LTD.
Reel/Frame 021232/0839 →
Continuity (4)
Continuation In Part 11211098 · Aug 25, 2005
Provisional Application 60909074 · Mar 30, 2007
Provisional Application 60604433 · Aug 26, 2004
Related Publication 20080299084A1 · Dec 4, 2008